Skip to main content
Premium Trial:

Request an Annual Quote

Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial

NEW YORK – Rain Therapeutics said on Thursday it has inked an agreement with Tempus, under which the Chicago-based firm will provide testing and patient matching services for Rain's Phase II tumor-agnostic basket trial for its investigational drug RAIN-32.

Tempus will provide centralized tumor testing and patient matching services through its Connect & TIME Trial Network platform. Specifically, it will evaluate patients with solid tumors for pre-specified MDM2 amplification levels and normal p53 status using its DNA- and RNA-based tumor sequencing tests, Tempus xT and Tempus xE, as well as conduct comprehensive tumor profiling to determine if they are eligible to receive Rain's MDM2 inhibitor RAIN-32 within the Phase II basket trial.

Earlier this week, Rain announced a similar partnership with Caris Life Sciences for this same study. Caris is providing whole-exome and -transcriptome sequencing services to help Rain identify patients eligible for the trial slated to begin in the second half of 2021.

The Newark, California-based company licensed RAIN-32, previously called milademetan, from Daiichi Sankyo in September. The firm is also planning two other trials of the drug, a Phase III study in MDM2-amplified liposarcoma and a Phase II trial in intimal sarcoma.

RAIN-32 showed activity in both MDM2-amplified liposarcoma and solid tumors in a Phase I trial presented last year. In patients with liposarcoma the disease control rate was 58.5 percent, and among patients with non-liposarcoma solid tumors the disease control rate was 32.4 percent.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.